1. Preface

• 1.1 Report Description and Scope

• 1.2 Research Objectives

• 1.3 Key Assumptions and Limitations

• 1.4 Target Audience

2. Executive Summary

• 2.1 Market Overview and Snapshot

• 2.2 Key Market Findings and Highlights

• 2.3 Market Size Estimation and Forecast Summary

• 2.4 Key Trends at a Glance

• 2.5 Recommendations for Market Participants

3. Research Methodology

• 3.1 Research Design and Approach

• 3.2 Primary Research (Vascular Surgeons, Interventional Radiologists, Hemodialysis Nephrologists, Cardiothoracic Surgeons, Hospital Procurement Managers, Medical Device Regulatory Affairs Specialists, KOL Interactions)

• 3.3 Secondary Research (Annual Reports, FDA 510(k)/PMA Device Approval Databases, EMA Cardiovascular Device Regulatory Data, WHO Global CVD and CKD Statistics, CDC Peripheral Artery Disease Data, Journal of Vascular Surgery, European Journal of Vascular and Endovascular Surgery, Journal of the American College of Surgeons, ClinicalTrials.gov, USRDS Annual Data Report on CKD/ESRD, CDSCO India Medical Device Rules, NMPA China Device Approvals, PMDA Japan Registration Data)

• 3.4 Top-Down and Bottom-Up Estimation Approach

• 3.5 Data Triangulation and Validation

• 3.6 Market Forecast Assumptions and Key Parameters

4. Market Overview

• 4.1 Introduction to Vascular Grafts and Their Critical Role in Restoring Blood Flow in Cardiovascular, Peripheral Vascular, and Renal Disease Management

• 4.2 Historical Market Background and Evolution (Autologous Saphenous Vein Grafts → Synthetic PTFE/Polyester Grafts → Cryopreserved Allografts → ePTFE Endovascular Stent Grafts → Tissue-Engineered Bioengineered Grafts → 3D-Printed Patient-Specific Conduits → Smart Self-Cleaning Grafts)

• 4.3 Market Scope and Definition

  • 4.3.1 Endovascular Stent Grafts (Aortic Aneurysm EVAR/TEVAR Applications)

  • 4.3.2 Hemodialysis Access Grafts (AV Graft for ESRD/CKD Vascular Access)

  • 4.3.3 Bypass Grafts (Coronary Artery Bypass Grafting — CABG, Peripheral Bypass)

  • 4.3.4 Peripheral Vascular Grafts (PAD, Lower Limb Revascularization)

  • 4.3.5 Vascular Grafts for Aortic Disease (TAA, AAA, Aortic Dissection)

  • 4.3.6 Others (Carotid, Renal, Visceral, and Specialty Vascular Bypass Conduits)

• 4.4 Parent Market and Adjacent Market Analysis (Cardiovascular Medical Devices, Vascular Stents, Drug-Coated Balloons, Mechanical Circulatory Support, Interventional Radiology Devices, Hemodialysis Equipment)

• 4.5 Regulatory Overview

  • 4.5.1 U.S. FDA — 510(k) Clearance and PMA Approval for Vascular Grafts (GORE EXCLUDER AAA Endoprosthesis PMA; Endologix VELA Proximal Endoprosthesis Approval); FDA Guidance on Surgical Mesh for Vascular Applications (ISO 7198)

  • 4.5.2 EU MDR 2017/745 — Class III Active Implantable Vascular Device Compliance; CE Mark Requirements for EVAR/TEVAR Stent Grafts; EMA Performance Evaluation for Bioresorbable Vascular Scaffolds

  • 4.5.3 MicroPort Scientific Corporation — TFDA (Thailand FDA) Approval for Castor Branched Aortic Stent-Graft, Hercules Thoracic Stent Graft System, and Minos Abdominal Aortic Stent-Graft (September 2023)

  • 4.5.4 India CDSCO Medical Device Rules 2017 — Vascular Graft Import/Manufacture Registration; NPPA Price Governance for Vascular Implants

  • 4.5.5 Japan PMDA Registration Requirements for Vascular Grafts and Endoprostheses; NHI Reimbursement Tier Classification

  • 4.5.6 China NMPA Class III Medical Device Registration for Vascular Grafts and Endovascular Stent Systems

  • 4.5.7 ISO 10993 Biocompatibility, ISO 7198 (Cardiovascular Implants — Vascular Prostheses), ASTM F2510, ANSI/AAMI VP20 Standards for Vascular Graft Performance

• 4.6 Technology and Innovation Timeline

  • 4.6.1 1950s–1970s: Autologous Vein Harvesting and First-Generation Polyester (Dacron) Prosthetic Grafts

  • 4.6.2 1980s–1990s: ePTFE (Expanded PTFE — GORE-TEX) Grafts for Hemodialysis Access and Peripheral Bypass

  • 4.6.3 1991–2000s: Endovascular Stent Graft (EVAR for AAA — Parodi 1991; TEVAR for Thoracic Aneurysm)

  • 4.6.4 2000s–2015: Fenestrated, Branched, and Custom EVAR Systems (Fenestrated EVAR for Juxtarenal AAA)

  • 4.6.5 2016–2023: Tissue-Engineered Vascular Grafts (TEVGs) and Bioengineered Decellularized Scaffolds; Cryopreserved Allografts; Heparin-Bonded ePTFE Grafts (GORE PROPATEN)

  • 4.6.6 2023–2026: Self-Cleaning Vascular Grafts (University of Pittsburgh February 2023 — Clot-Repelling Grafts for Coronary Bypass), 3D-Printed Patient-Specific Vascular Conduits, Cell-Seeded Bioengineered Grafts, Electrospun Polyurethane (ePU) Grafts (MDPI November 2023)

  • 4.6.7 Emerging: CRISPR-Enabled Endothelial Cell Seeding, Smart Sensor-Embedded Vascular Grafts for Real-Time Patency Monitoring, AI-Guided 3D-Printed Custom Aortic Endoprostheses

• 4.7 Vascular Graft Types Comparison: Synthetic (PTFE/Polyester) vs. Biological (Autograft/Allograft/Xenograft) vs. Hybrid vs. Bioengineered Grafts — Patency Rates, Infection Risk, Biocompatibility, Durability, and Clinical Application Suitability

• 4.8 Open Surgical Bypass vs. Endovascular (EVAR/TEVAR) vs. Hybrid Vascular Repair: Clinical Outcomes, Recovery Timelines, Mortality Rates, and Patient Selection Framework

5. Market Dynamics

• 5.1 Market Drivers

  • 5.1.1 Rising Global Prevalence of Cardiovascular Diseases — WHO Reports 17.9 Million CVD Deaths Annually; Cardiovascular Disease Claims a U.S. Life Every 33 Seconds (~699,659 Deaths in 2022 per CDC)

  • 5.1.2 Growing Burden of Peripheral Artery Disease (PAD) — Approximately 113 Million Global PAD Patients (Frontiers 2022); 6.5 Million Adults Over 40 in the U.S. Living with PAD (CDC)

  • 5.1.3 Rising Incidence of End-Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD) — 37 Million U.S. Adults Affected by CKD (NIDDK May 2023); 434.3 Million CKD Cases in Asia Pacific Driving Hemodialysis Access Graft Demand

  • 5.1.4 Technological Advancement in Endovascular Stent Grafts — EVAR/TEVAR Adoption Reducing Open Surgery Mortality and Enabling Minimally Invasive Aortic Aneurysm Repair

  • 5.1.5 Growing Adoption of MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) Procedure — Enhanced Safety, Low Mortality Rate, and Compatibility with Cardiopulmonary Bypass Driving Demand for Coronary Bypass Grafts

  • 5.1.6 Increasing Hemodialysis Patient Population — USRDS 2023 Annual Report: 500,000+ U.S. ESRD Patients on Dialysis; Rising AV Graft Utilization for Vascular Access Where AV Fistula Fails

  • 5.1.7 Rapid Growth in Tissue-Engineered and Bioengineered Vascular Grafts R&D — CIRM USD 3 Million Grant to UC Davis for Intelligent Hemodialysis Vascular Graft Development (May 2022)

• 5.2 Market Restraints

  • 5.2.1 High Cost of Vascular Graft Procedures — EVAR/TEVAR Procedures Ranging USD 15,000–USD 30,000+; Open Aortic Repair USD 20,000–USD 50,000 in the U.S., Limiting Access in Emerging Markets

  • 5.2.2 Post-Surgical Complications — Intimal Hyperplasia, Graft Thrombosis, Anastomotic Stenosis, Pseudoaneurysm Formation, and Prosthetic Graft Infection Reducing Long-Term Patency in Synthetic Grafts

  • 5.2.3 Limited Availability of Small-Caliber Synthetic Grafts (<6 mm) with Adequate Long-Term Patency for Coronary and Tibial Artery Bypass Applications

  • 5.2.4 Regulatory Complexity — Multi-Jurisdictional Class III Device Registration (FDA PMA, EU MDR, NMPA, PMDA, CDSCO) Extending Time-to-Market for Novel Vascular Graft Platforms

  • 5.2.5 Shortage of Skilled Vascular Surgeons and Endovascular Specialists in Developing Regions Limiting Procedure Volume Growth

• 5.3 Market Opportunities

  • 5.3.1 Tissue-Engineered Vascular Grafts (TEVGs) — Cell-Seeded Bioengineered Grafts Enabling Immune-Compatible Autologous-Like Conduits; UC Davis CIRM Grant for Intelligent Hemodialysis Graft; Humacyte HAVs (Human Acellular Vessels) FDA New Drug Application Review

  • 5.3.2 Self-Cleaning and Antithrombotic Vascular Grafts — University of Pittsburgh Clot-Repelling Coronary Bypass Graft (February 2023) and Heparin-Bonded ePTFE (GORE PROPATEN) Reducing Post-Implant Thrombosis

  • 5.3.3 3D-Printed Patient-Specific Vascular Conduits — Personalized Aortic Endoprosthesis for Complex Anatomy (Fenestrated/Branched EVAR), Bioprinted TEVG Scaffolds, and AI-Guided Surgical Planning Platforms

  • 5.3.4 Electrospun Polyurethane (ePU) Vascular Grafts — Promising Synthetic Alternatives for Small-Caliber Vascular Surgery (MDPI November 2023 Study) Reducing Neointimal Formation Risk

  • 5.3.5 Emerging Market Expansion — India, China, Brazil, Southeast Asia Increasing Vascular Surgery Procedure Volumes via Government Healthcare Infrastructure Investment and Growing Interventional Radiology Capacity

  • 5.3.6 W.L. Gore & Associates Acquisition of InnAVasc Medical — Enhanced Dialysis Graft Platform Reducing Excessive Bleeding and Back/Side-Wall Injuries During Cannulation (August 2022)

  • 5.3.7 Smart Vascular Grafts With Embedded Sensors — Real-Time Flow Monitoring, Pressure-Sensing Grafts, and IoT-Connected Patency Surveillance for Remote Graft Health Management

• 5.4 Market Challenges

  • 5.4.1 Clinical Validation Gap for Novel Bioengineered and Tissue-Engineered Grafts — Limited Long-Term (5–10 Year) Real-World Patency and Safety Data Relative to Established ePTFE and Polyester Platforms

  • 5.4.2 Reimbursement Uncertainty for Premium TEVG, Heparin-Bonded, and Hybrid Graft Technologies Across CMS, European HTA, and Emerging Market Payer Systems

  • 5.4.3 Intimal Hyperplasia and Graft Failure at Anastomotic Sites — Fundamental Biological Challenge Limiting Small-Caliber Synthetic Graft Performance in High-Resistance Vascular Beds

  • 5.4.4 Managing Post-EVAR Endoleak Surveillance — Lifelong CT/MRI Monitoring Requirements Increasing Total Cost of Care for Stent-Graft Recipients

6. Market Trends and Key Insights

• 6.1 Endovascular Stent Grafts Dominate by Product Revenue (63.78% Share in 2023 per GVR) — EVAR/TEVAR Minimally Invasive Approach Reducing Surgical Mortality and Hospital Stay Vs. Open Aortic Surgery

• 6.2 Synthetic Vascular Grafts Lead Raw Material Segment (51.64% Share in 2023 per GVR) — ePTFE and Polyester Platforms Providing Proven Long-Term Performance; Hybrid Grafts Recording Fastest CAGR

• 6.3 Cardiac Aneurysm Application Holds Largest Market Share (50.93% Share in 2023 per GVR) — AAA/TAA EVAR/TEVAR Procedures Expanding With Aging Population and Improved Screening Programs

• 6.4 Vascular Occlusion (PAD) Segment Recording Fastest CAGR — 113 Million Global PAD Patients (Frontiers 2022) Driving Peripheral Bypass and Endovascular Revascularization Procedure Growth

• 6.5 Tissue-Engineered Vascular Grafts Moving Toward Commercialization — Humacyte Human Acellular Vessel (HAV) FDA Review and Cell-Seeded TEVG Clinical Trial Surge (Mordor +0.80% CAGR Impact)

• 6.6 3D-Printed Patient-Specific Vascular Conduits Entering Clinical Practice — Fenestrated and Branched EVAR Custom Systems Gaining Regulatory Traction for Complex Juxtarenal and Thoracoabdominal Aneurysms (Mordor +0.70% CAGR Impact)

• 6.7 Strategic Acquisitions Reshaping Competitive Landscape — W.L. Gore Acquisition of InnAVasc Medical (August 2022) and Artivion Expansion in Cardiac Surgery

• 6.8 Self-Expanding Off-the-Shelf Endovascular Stent Grafts Gaining Momentum in Emerging Markets — Reducing Dependency on Open Surgical Expertise; MicroPort TFDA Approvals (September 2023) Expanding Southeast Asia Footprint (Mordor +0.90% CAGR Impact)

7. Impact Assessment

• 7.1 Impact of COVID-19 on the Vascular Grafts Market

  • 7.1.1 Pre-COVID Market Scenario

  • 7.1.2 Pandemic Impact: CMS Elective Vascular Surgery Classification as Non-Urgent, Significant Open Bypass Procedure Volume Drop, Hospital Resource Reallocation, Supply Chain Disruptions for Sterile Implant Packaging

  • 7.1.3 Post-COVID Recovery: Pent-Up Aortic Aneurysm and PAD Procedure Backlog Recovery, EVAR Preference Accelerated as Safer Elective Alternative, Telehealth-Linked Pre-Op Vascular Assessment Growth

• 7.2 Macroeconomic Indicators and Their Influence on Market Growth

  • 7.2.1 Rising Global Healthcare Expenditure Driving Premium EVAR/TEVAR Stent Graft Adoption in High-Income Markets

  • 7.2.2 Healthcare Budget Constraints in Europe and Emerging Markets Favoring Cost-Effective Synthetic Bypass Grafts Over Premium TEVG Platforms

  • 7.2.3 China and India Healthcare Infrastructure Investment — Expanding Vascular Surgery Unit Count, Interventional Radiology Suite FDI, and Domestic Graft Manufacturing Capacity

• 7.3 Impact of EU MDR 2017/745 Class III Compliance, FDA EVAR/TEVAR Post-Market Surveillance Requirements, India CDSCO Medical Device Rules, China NMPA Class III EVAR Registration, and Japan PMDA NHI Reimbursement Reclassification

• 7.4 Geopolitical Factors — U.S.-China Trade Tensions Impacting Polyester and PTFE Polymer Component Imports; BIOSECURE Act Implications for China-Manufactured Vascular Implant Components; Southeast Asia FDI Incentives for Medical Device Manufacturing

8. Strategic Framework Analysis

• 8.1 Value Chain Analysis

  • 8.1.1 Raw Material and Biomaterial Suppliers (Medical-Grade ePTFE, Polyester/Dacron Yarn, Polyurethane Polymer, Biological Tissue Sources — Bovine/Porcine Pericardium, Human Cadaver Vessels, Extracellular Matrix Scaffolds)

  • 8.1.2 Vascular Graft Fabric and Component Manufacturers (Weaving, Knitting, Electrospinning, and Extrusion Technology Specialists)

  • 8.1.3 Graft Surface Treatment and Coating Specialists (Heparin-Bonding — GORE PROPATEN Technology; Albumin Sealing; Antimicrobial Coating; Antithrombotic Surface Functionalization)

  • 8.1.4 Endovascular Stent-Graft System Manufacturers (Nitinol Stent Frame + Fabric Graft Integration: Medtronic Endurant/Valiant, GORE EXCLUDER/TAG, Cook Zenith, Endologix AFX, MicroPort Castor/Hercules/Minos)

  • 8.1.5 Bioengineering and Tissue-Engineering Research and Commercialization Organizations (Humacyte HAV, UC Davis CIRM Program, University of Pittsburgh Self-Cleaning Graft)

  • 8.1.6 Sterilization, Validated Packaging, and Cold-Chain/Cryogenic Storage Partners (Cryopreserved Allograft Tissue Banks)

  • 8.1.7 End Users — Hospitals, Vascular Surgery Units, Transplant Centers, Hemodialysis Access Centers, ASCs, and Cardiac Surgery Programs

• 8.2 Supply Chain Analysis and Risk Assessment (ePTFE/Polyester Polymer Sourcing, Nitinol Stent Frame Component Availability, Cryopreserved Allograft Cold-Chain Integrity, China-Manufactured Component Trade Risk)

• 8.3 Porter's Five Forces Analysis

  • 8.3.1 Threat of New Entrants (Bioengineering TEVG Startups — Humacyte, Xeltis, Biostage; 3D-Printed Graft Innovators; AI-Guided Custom EVAR Platform Developers)

  • 8.3.2 Bargaining Power of Buyers (Hospital GPOs, National Health Systems, ESRD Network Hemodialysis Center Procurement Groups)

  • 8.3.3 Bargaining Power of Suppliers (ePTFE Polymer Manufacturers, Nitinol Stent Frame OEMs, Biological Tissue Banks, Heparin-Bonding Technology Licensors)

  • 8.3.4 Threat of Substitute Therapies (Drug-Coated Balloons and Stents for PAD; Endovascular Thrombectomy for Acute Occlusion; AV Fistula as First-Line Hemodialysis Access Over AV Graft; Optimal Medical Therapy for Stable PAD)

  • 8.3.5 Competitive Rivalry Among Existing Players (Gore 18.3% Market Share; Top 5 — Abbott, Artivion, Getinge, Gore, LeMaitre, Medtronic — ~65% Collective Share per GMI)

• 8.4 SWOT Analysis of the Overall Market

• 8.5 Pricing Analysis and Trends by Product Type, Graft Material, Procedure, and Region

  • 8.5.1 Endovascular Stent Graft Pricing — EVAR System USD 8,000–USD 18,000; TEVAR System USD 10,000–USD 25,000 (Complex Fenestrated/Branched USD 30,000–USD 60,000)

  • 8.5.2 Synthetic Bypass Graft Pricing — ePTFE Bypass Graft USD 500–USD 1,500; Polyester/Dacron Graft USD 300–USD 1,000; Heparin-Bonded ePTFE (GORE PROPATEN) ~30–50% Premium Over Standard ePTFE

  • 8.5.3 Hemodialysis AV Access Graft Pricing — Standard ePTFE AV Graft USD 800–USD 2,000; Gore InnAVasc-Enhanced Platform Premium Tier Pricing

  • 8.5.4 Bioengineered/TEVG Pricing — Humacyte HAV Expected Premium of 2–3× Standard ePTFE Given Immunocompatibility and Patency Advantages

• 8.6 Technology Landscape and Innovation Matrix

  • 8.6.1 ePTFE (Expanded PTFE) Vascular Grafts — Standard of Care for AV Access and Peripheral Bypass; GORE PROPATEN Heparin-Bonded Variant for Extended Patency

  • 8.6.2 Polyester/Dacron Vascular Grafts — Woven and Knitted Variants for Aortic Bypass; Velour-Lined Protein-Sealed Designs

  • 8.6.3 Endovascular Stent Graft Systems — EVAR (Endurant IIs, EXCLUDER, Zenith, AFX, Ovation), TEVAR (Valiant Navion, TAG, TX2, Relay NBS Plus, Castor Branched, Hercules, Minos)

  • 8.6.4 Fenestrated and Branched EVAR (F-EVAR/B-EVAR) Custom Systems for Complex Juxtarenal and Thoracoabdominal Aneurysms

  • 8.6.5 Tissue-Engineered Vascular Grafts (TEVGs) — Humacyte HAV, Cell-Seeded Decellularized Scaffolds, Bioprinted TEVG Platforms

  • 8.6.6 Electrospun Polyurethane (ePU) Grafts — Antithrombogenic Synthetic Alternative for Small-Caliber Vascular Applications

  • 8.6.7 Self-Cleaning Vascular Grafts — University of Pittsburgh Platelet-Repelling Grafts for CABG; Antimicrobial-Coated Infection-Resistant Grafts

  • 8.6.8 3D-Printed and AI-Guided Patient-Specific Vascular Conduits — Custom Aortic Endoprostheses, Digital Pre-Op Planning Integration

  • 8.6.9 Smart Sensor-Embedded Vascular Grafts — IoT-Connected Flow and Pressure Monitoring for Real-Time Patency Surveillance

• 8.7 IP and Patent Landscape (Heparin-Bonding Technology, ePTFE Manufacturing, Fenestrated/Branched EVAR Design, Bioengineered Scaffold Seeding, Electrospun ePU Architecture, 3D-Printed Patient-Specific Conduit Patent Clusters)

• 8.8 M&A Activity, Strategic Partnerships, and Investment Landscape (2022–2026: W.L. Gore–InnAVasc Medical August 2022, Artivion Cardiac Surgery Expansion, CIRM–UC Davis USD 3M Hemodialysis Graft Grant May 2022)

• 8.9 Regulatory and Standards Landscape by Region (FDA 510(k)/PMA, EU MDR 2017/745 Class III, ISO 10993/ISO 7198, ASTM F2510, India CDSCO, China NMPA, Japan PMDA, Brazil ANVISA)

• 8.10 Reimbursement Landscape — U.S. Medicare EVAR/CABG DRG Coverage; European HTA (NICE, G-BA, HAS) EVAR Technology Appraisals; Japan PMDA NHI EVAR Reimbursement Tier; India NPPA Vascular Implant Price Governance

• 8.11 Drivers Impact Analysis on CAGR

  • 8.11.1 Expanding Off-the-Shelf Endovascular Stent-Graft Adoption: +0.90% CAGR Impact

  • 8.11.2 Clinical Trial Surge for Cell-Seeded Bioengineered Grafts: +0.80% CAGR Impact

  • 8.11.3 Emergence of 3D-Printed Patient-Specific Vascular Conduits: +0.70% CAGR Impact

9. Global Vascular Grafts Market — By Product

• 9.1 Overview and Market Size, 2026–2033

• 9.2 Endovascular Stent Grafts

  • 9.2.1 Abdominal Aortic Aneurysm (AAA) Stent Grafts — EVAR Systems (Medtronic Endurant IIs, GORE EXCLUDER, Cook Zenith, Endologix Ovation/AFX2)

  • 9.2.2 Thoracic Aortic Aneurysm (TAA) / Aortic Dissection Stent Grafts — TEVAR Systems (Medtronic Valiant Navion, GORE TAG, Cook TX2, Relay NBS Plus, Vascular Graft Solutions Palindrome)

  • 9.2.3 Fenestrated and Branched Endovascular Stent Grafts — Custom F-EVAR/B-EVAR (Cook Zenith Fenestrated, GORE EXCLUDER Iliac Branch)

  • 9.2.4 Off-the-Shelf Branched Aortic Stent Grafts — MicroPort Castor, Gore IBE (Iliac Branch Endoprosthesis)

  • 9.2.5 Market Size, Share, and Forecast (63.78% Dominant Share in 2023 per GVR — 89.9% per GVR FAQ for Stent Graft Combined; Minimally Invasive EVAR/TEVAR Reducing Open Aneurysm Surgery, Guideline-Driven Adoption for AAA >5.5 cm)

• 9.3 Hemodialysis Access Grafts

  • 9.3.1 Standard ePTFE AV Access Grafts — Straight, Loop, and Curved Configurations for Forearm and Upper Arm Access

  • 9.3.2 Heparin-Bonded AV Access Grafts — GORE PROPATEN Heparin-Bonded Hemodialysis Graft

  • 9.3.3 Gore InnAVasc-Enhanced Graft Platform — Reduced Cannulation Bleeding and Back/Side-Wall Injury Design (Post-Acquisition August 2022)

  • 9.3.4 Bioengineered Hemodialysis Access Grafts — Humacyte Human Acellular Vessel (HAV) for ESRD Vascular Access; CIRM–UC Davis Intelligent Hemodialysis Graft (May 2022)

  • 9.3.5 Market Size, Share, and Forecast (Significant CAGR: 500,000+ U.S. ESRD Dialysis Patients; Rising Global CKD Burden in Asia Pacific — 434.3 Million Cases; AV Graft Second-Line When AV Fistula Fails)

• 9.4 Bypass Grafts

  • 9.4.1 Coronary Artery Bypass Grafting (CABG) Conduits — Saphenous Vein Graft (SVG), Internal Mammary Artery (IMA) Graft, Radial Artery Graft, Electrospun ePU Synthetic Graft Alternatives

  • 9.4.2 MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) — Less Invasive Bypass Conduit Applications

  • 9.4.3 Self-Cleaning Coronary Bypass Grafts — University of Pittsburgh Platelet-Repelling Clot-Resistant Graft Platform (February 2023 Publication)

  • 9.4.4 Peripheral Bypass Conduits — Above-Knee/Below-Knee Femoral-Popliteal Bypass, Tibial Bypass Grafts

  • 9.4.5 Market Size, Share, and Forecast (Stable Premium Niche: CABG Remains Gold Standard for Multi-Vessel CAD; Growing Peripheral Bypass Volume Driven by PAD Prevalence)

• 9.5 Peripheral Vascular Grafts

  • 9.5.1 ePTFE Peripheral Vascular Grafts — Femoropopliteal, Femoro-Tibial, and Aortobifemoral Bypass Conduits

  • 9.5.2 Polyester/Dacron Peripheral Bypass Grafts — Bifurcated Aortobifemoral Dacron Graft (Woven and Knitted)

  • 9.5.3 Heparin-Bonded ePTFE Peripheral Bypass (GORE PROPATEN) for Extended Patency in Below-Knee Bypass

  • 9.5.4 Market Size, Share, and Forecast (Fastest Growing Product Segment CAGR: Rising PAD Prevalence Globally; 113 Million Global PAD Patients — Frontiers 2022; Growing Endovascular-Hybrid PAD Revascularization Adoption)

• 9.6 Vascular Grafts for Aortic Disease

  • 9.6.1 Open Surgical Aortic Graft Replacement — Polyester Tube/Bifurcated Graft for Elective/Emergent Aortic Repair

  • 9.6.2 Thoracoabdominal and Visceral Hybrid Repair Grafts (Branched Aortic Prostheses — Crawford Classification I–V Repairs)

  • 9.6.3 Market Size, Share, and Forecast

• 9.7 Others

  • 9.7.1 Carotid Patch Angioplasty Grafts (ePTFE, Polyester, Bovine Pericardium Carotid Patches)

  • 9.7.2 Renal and Visceral Artery Bypass Grafts

  • 9.7.3 Market Size, Share, and Forecast

10. Global Vascular Grafts Market — By Raw Material

• 10.1 Overview and Market Size, 2026–2033

• 10.2 Synthetic Vascular Grafts

  • 10.2.1 Polytetrafluoroethylene (PTFE) Grafts

    • 10.2.1.1 Standard ePTFE Grafts (GORE-TEX Medical) — Hemodialysis Access, Peripheral Bypass, CABG

    • 10.2.1.2 Heparin-Bonded ePTFE Grafts (GORE PROPATEN) — Extended Patency for Below-Knee and High-Risk Bypass

    • 10.2.1.3 Carbon-Impregnated ePTFE Grafts — Enhanced Thromboresistance

    • 10.2.1.4 Market Size, Share, and Forecast

  • 10.2.2 Polyester (PET/Dacron) Grafts

    • 10.2.2.1 Woven Polyester Grafts (Low Porosity, High Radial Strength — Aortic Replacement)

    • 10.2.2.2 Knitted Polyester Grafts (High Porosity, Flexible, Protein-Sealed — Getinge Intervascular, B. Braun Aesculap)

    • 10.2.2.3 Velour-Lined and Collagen/Albumin-Sealed Polyester Grafts

    • 10.2.2.4 Market Size, Share, and Forecast

  • 10.2.3 Polyurethane Grafts

    • 10.2.3.1 Electrospun Polyurethane (ePU) Grafts — Small-Caliber Vascular Surgery Applications (MDPI November 2023 Study)

    • 10.2.3.2 Standard Polyurethane Vascular Grafts (Complex Vascular Trauma Applications)

    • 10.2.3.3 Market Size, Share, and Forecast

  • 10.2.4 Market Size, Share, and Forecast (51.64% Dominant Share in 2023 per GVR: Established Mechanical Performance, Long-Term Patency Data, Cost-Effectiveness, Wide Availability)

• 10.3 Biological Vascular Grafts

  • 10.3.1 Autografts

    • 10.3.1.1 Greater Saphenous Vein (GSV) Graft — Gold Standard Conduit for CABG and Below-Knee Peripheral Bypass

    • 10.3.1.2 Internal Mammary Artery (IMA) / Radial Artery Graft — Superior Long-Term Patency for CABG (Left IMA 10-Year Patency >90%)

    • 10.3.1.3 Market Size, Share, and Forecast

  • 10.3.2 Allografts

    • 10.3.2.1 Cryopreserved Human Saphenous Vein Allografts — Infected Field, Redo Bypass Applications

    • 10.3.2.2 Cryopreserved Arterial Allografts — Aortoiliac Reconstruction in Infected Fields

    • 10.3.2.3 Decellularized Allograft Scaffolds for Tissue Engineering Applications

    • 10.3.2.4 Market Size, Share, and Forecast

  • 10.3.3 Xenografts

    • 10.3.3.1 Bovine Carotid Artery Graft (Artegraft — NovaBay Pharmaceuticals) — Hemodialysis Access

    • 10.3.3.2 Bovine Pericardial Carotid Patch — Carotid Endarterectomy Patch Angioplasty

    • 10.3.3.3 Porcine Intestinal Submucosa (SIS)-Based Scaffolds

    • 10.3.3.4 Market Size, Share, and Forecast

• 10.4 Hybrid Vascular Grafts

  • 10.4.1 Synthetic + Biocompatible Biological Component Hybrid Grafts (PET/PTFE + Extracellular Matrix Scaffold Composites)

  • 10.4.2 Heparin-Coated Synthetic + Biological Matrix Hybrid Platforms

  • 10.4.3 Market Size, Share, and Forecast (Fastest Growing Raw Material Segment CAGR per GVR: Combining Mechanical Strength of Synthetic Grafts with Biocompatibility Advantages of Biological Materials; Reduced Thrombogenicity and Intimal Hyperplasia)

• 10.5 Biosynthetic Vascular Grafts

  • 10.5.1 Tissue-Engineered Vascular Grafts (TEVGs) — Humacyte Human Acellular Vessel (HAV)

  • 10.5.2 Cell-Seeded Biodegradable Scaffold Grafts — PLLA/PGA Polymer Backbone + Endothelial Cell Seeding

  • 10.5.3 Electrospun Biocomposite Grafts — Fibrous Scaffold + Bioactive Coating

  • 10.5.4 Market Size, Share, and Forecast (High-Growth Research-to-Commercial Translation Stage: Humacyte HAV FDA NDA Review; CIRM UC Davis Hemodialysis Graft Program)

11. Global Vascular Grafts Market — By Application

• 11.1 Overview and Market Size, 2026–2033

• 11.2 Cardiac Aneurysm (Aortic Aneurysm — AAA and TAA)

  • 11.2.1 Abdominal Aortic Aneurysm (AAA) — EVAR and Open Surgical Graft Repair (80,000 AAA Patients Aged 65–74 in England per John Wiley & Sons 2021; ~6,000 Deaths Annually in England and Wales)

  • 11.2.2 Thoracic Aortic Aneurysm (TAA) and Type B Aortic Dissection — TEVAR and Hybrid Open/Endovascular Repair

  • 11.2.3 Coronary Artery Aneurysm (CAA) Management

  • 11.2.4 Thoracoabdominal Aortic Aneurysm (TAAA) — Branched and Fenestrated EVAR/Open Repair

  • 11.2.5 Market Size, Share, and Forecast (50.93% Dominant Share in 2023 per GVR: Highest Procedure Volume, EVAR/TEVAR Guideline-Driven Adoption, Aging Population Expanding AAA Screening Programs)

• 11.3 Kidney Failure / Renal Failure (Hemodialysis Vascular Access)

  • 11.3.1 Hemodialysis AV Graft for ESRD Patients Where AV Fistula Maturation Fails or Exhausted Venous Access

  • 11.3.2 Market Size, Share, and Forecast (Significant CAGR: 37 Million U.S. CKD Adults; 434.3 Million Asia Pacific CKD Cases; Rising ESRD Dialysis Population Globally)

• 11.4 Vascular Occlusion (Peripheral Artery Disease — PAD)

  • 11.4.1 Femoral-Popliteal Bypass for Superficial Femoral Artery (SFA) Occlusion — TASC II C/D Lesions

  • 11.4.2 Tibial and Pedal Bypass for Critical Limb-Threatening Ischemia (CLTI) — Below-Knee ePTFE/Autologous Vein Bypass

  • 11.4.3 Aortobifemoral and Aortoiliac Bypass for Occlusive Aortoiliac Disease (Leriche Syndrome)

  • 11.4.4 Market Size, Share, and Forecast (Fastest Growing Application Segment CAGR: 113 Million Global PAD Patients — Frontiers 2022; ~10.5 Million New PAD Cases Annually; Rising Diabetic Foot and CLTI Burden)

• 11.5 Coronary Artery Disease (CAD) — Coronary Artery Bypass Grafting (CABG)

  • 11.5.1 Multi-Vessel CAD CABG — Off-Pump and On-Pump Surgical Bypass Using IMA, SVG, Radial Artery, or Synthetic Conduit

  • 11.5.2 MIDCAB (Minimally Invasive Direct CABG) — Less Invasive Bypass Approach

  • 11.5.3 Redo CABG — Cryopreserved Allograft or Alternative Synthetic Conduit for Exhausted Native Vessel

  • 11.5.4 Market Size, Share, and Forecast (Stable Demand: CABG Remains Gold Standard for Multi-Vessel and Left Main CAD; Self-Cleaning Graft Innovation Potentially Extending Long-Term Bypass Patency)

• 11.6 Others

  • 11.6.1 Carotid Endarterectomy (CEA) with Patch Angioplasty — Bovine Pericardial/ePTFE Carotid Patch

  • 11.6.2 Renal Artery Bypass (Renal Vascular Hypertension, Renovascular Disease)

  • 11.6.3 Visceral Artery Reconstruction (Celiac, SMA, IMA Bypass)

  • 11.6.4 Infection-Related Vascular Reconstruction — Cryopreserved Allograft Replacement for Infected Prosthetic Grafts

  • 11.6.5 Market Size, Share, and Forecast

12. Global Vascular Grafts Market — By End User

• 12.1 Overview and Market Size, 2026–2033

• 12.2 Hospitals

  • 12.2.1 Academic Medical Centers and Tertiary Vascular Surgery Programs

  • 12.2.2 Community Hospitals with Vascular Surgery and Interventional Radiology Programs

  • 12.2.3 Cardiac Surgery and Cardiothoracic Programs (CABG, Aortic Root Replacement)

  • 12.2.4 Market Size, Share, and Forecast (Dominant End User: Complex EVAR/TEVAR and Open Surgical Repair Volume, Critical Care, CSSD, Hybrid OR Infrastructure)

• 12.3 Specialty Clinics

  • 12.3.1 Vascular Surgery Specialty Clinics and Outpatient Vascular Practice Networks

  • 12.3.2 Interventional Radiology Clinics — Endovascular PAD Revascularization

  • 12.3.3 Hemodialysis Centers and Nephrology Clinics (Chronic AV Graft Monitoring and Maintenance)

  • 12.3.4 Market Size, Share, and Forecast (Significant CAGR: Growing Vascular Specialist Clinic Count; Rising PAD and ESRD Outpatient Case Load)

• 12.4 Ambulatory Surgical Centers (ASCs)

  • 12.4.1 ASC-Based Endovascular Peripheral Interventions (CMS-Approved PAD PVI Procedures)

  • 12.4.2 ASC-Based Hemodialysis Access Creation and Revision

  • 12.4.3 Market Size, Share, and Forecast (Fastest Growing End User: CMS ASC Coverage Expansion for Vascular Procedures; Payer Incentives for Outpatient Revascularization)

• 12.5 Others

  • 12.5.1 Military and Trauma Medical Facilities (Combat Vascular Injury Reconstruction)

  • 12.5.2 Research and Academic Medical Centers Conducting Vascular Graft Clinical Trials

  • 12.5.3 Market Size, Share, and Forecast

13. Global Vascular Grafts Market — By Region

• 13.1 Market Overview by Geography

• 13.2 North America

  • 13.2.1 Market Size and Forecast (40.90% Dominant Share in 2023 per GVR; USD 2.97 Billion in 2026 per CMI; U.S. Vascular Graft Market USD 1.50 Billion in 2025 per Precedence)

  • 13.2.2 United States (CDC 6.5 Million PAD Adults Over 40; 37 Million CKD Adults — NIDDK May 2023; 699,659 CVD Deaths in 2022; Gore 18.3% Global Market Share; FDA EVAR/TEVAR Post-Market Surveillance Programs)

  • 13.2.3 Canada

  • 13.2.4 Key Drivers, Trends, and Market Dynamics

• 13.3 Europe

  • 13.3.1 Market Size and Forecast (EU MDR Class III Compliance Cycle Driving Premium Platform Upgrades; NICE/G-BA Technology Appraisals for EVAR/TEVAR)

  • 13.3.2 Germany (Largest European Market — CHD Leading Cause of Death in Germany; 121,172 CHD Deaths in 2021; 45,181 Acute MIs — Medscape October 2023; Getinge AB Vascular Graft Manufacturing Hub)

  • 13.3.3 United Kingdom (British Heart Foundation 39,000+ Cardiovascular Deaths in England 2022; NHS NICE EVAR Technology Appraisal TA167/TA388; Growing EVAR/TEVAR Procedure Volumes)

  • 13.3.4 France (SCA ~20% of European Deaths — EC Data; Sanofi/Hospital Infrastructure as End-User Base; HAS Vascular Surgery Cost-Effectiveness Reviews)

  • 13.3.5 Italy

  • 13.3.6 Spain

  • 13.3.7 Scandinavia (Denmark, Sweden, Norway — High CVD Research Output; Swedish Vascular Registry Data)

  • 13.3.8 Rest of Europe

  • 13.3.9 Key Drivers, Trends, and Market Dynamics

• 13.4 Asia Pacific

  • 13.4.1 Market Size and Forecast (Fastest Growing Region: 434.3 Million CKD Cases; Japan 13.3 Million CKD Patients; China Aging Population 14.9% of Total; India Diabetes/Hypertension PAD Drivers)

  • 13.4.2 Japan (Fastest CAGR Within Region — CKD 13.3 Million Patients per World Kidney Program; PMDA EVAR/TEVAR Reimbursement; Japan Lifeline Domestic Vascular Graft Distribution)

  • 13.4.3 China (Significant CAGR — Aging Population 14.9% per Global Times; NMPA MicroPort Castor/Hercules/Minos Approvals; Domestic Vascular Graft Manufacturing Expansion)

  • 13.4.4 India (CDSCO Medical Device Rules, Rising PAD and ESRD Burden, Medical Tourism CABG/EVAR Hub, Domestic ePTFE Graft Manufacturing Scale-Up)

  • 13.4.5 South Korea (MFDS Approvals, Samsung Medical Center EVAR Program)

  • 13.4.6 Australia (Aging Population, NHMRC-Funded Vascular Research, TGA-Cleared EVAR Systems)

  • 13.4.7 Southeast Asia (Thailand — MicroPort TFDA Approvals September 2023; Malaysia, Vietnam FDI Medical Device Incentives)

  • 13.4.8 Rest of Asia Pacific

  • 13.4.9 Key Drivers, Trends, and Market Dynamics

• 13.5 Latin America

  • 13.5.1 Market Size and Forecast (Fastest CAGR in Region: Government Healthcare Spending Growth, Skilled Healthcare Professionals, Multinational Medical Company Focus on Untapped Markets)

  • 13.5.2 Brazil (Aging Population, Rising CVD Burden, Positive Political/Economic Stability Post-2022, Endologix Alto AAA Stent Graft Argentina/Canada Approval May 2021)

  • 13.5.3 Mexico

  • 13.5.4 Argentina

  • 13.5.5 Rest of Latin America

  • 13.5.6 Key Drivers, Trends, and Market Dynamics

• 13.6 Middle East and Africa

  • 13.6.1 Market Size and Forecast (High Economic Development, Improved Healthcare Facilities, Unmet Clinical Needs in Emerging Markets)

  • 13.6.2 GCC Countries (Saudi Arabia — High Unmet Clinical Needs, Rising Disposable Income, Vision 2030 Healthcare Investment; UAE, Kuwait)

  • 13.6.3 South Africa

  • 13.6.4 North Africa and Central Africa

  • 13.6.5 Rest of Middle East and Africa

  • 13.6.6 Key Drivers, Trends, and Market Dynamics

14. Competitive Landscape

• 14.1 Market Structure and Competitiveness Overview (Moderately Concentrated: Gore 18.3% Market Share, Top 5 — Abbott, Artivion, Getinge, Gore, LeMaitre, Medtronic — ~65% Collective Share per GMI; Active M&A and Technology Innovation Among Mid-Tier Players)

• 14.2 Market Share Analysis of Key Players

• 14.3 Competitive Positioning Matrix

• 14.4 Key Strategies Adopted by Market Leaders

  • 14.4.1 Portfolio Innovation and Regulatory Approvals — MicroPort Castor/Hercules/Minos TFDA Thailand Approvals (September 2023); Gore InnAVasc Hemodialysis Graft Enhancement Post-Acquisition

  • 14.4.2 Strategic M&A for Platform and Technology Expansion — W.L. Gore Acquisition of InnAVasc Medical (August 2022) for Enhanced Dialysis Access Graft; Artivion Cardiac Surgery Portfolio Expansion

  • 14.4.3 Bioengineering and Next-Generation Graft R&D — CIRM–UC Davis USD 3M Intelligent Hemodialysis Graft Grant (May 2022); Humacyte HAV FDA NDA Review; University of Pittsburgh Self-Cleaning CABG Graft

  • 14.4.4 Emerging Market Expansion — Endologix Alto System Argentina/Canada Launch (May 2021); MicroPort Southeast Asia Regulatory Filing Strategy; LeMaitre APAC Distribution Partnerships

  • 14.4.5 Fenestrated/Branched EVAR Premium Platform Leadership — Cook Medical Zenith Fenestrated, Gore EXCLUDER Iliac Branch, Medtronic Valiant Navion Complex Aortic Repair Portfolio

• 14.5 Recent Developments and Industry News (2024–2026)

• 14.6 Technology and Product Pipeline Analysis

15. Company Profiles
(The final report includes a complete list of companies)

• 15.1 W.L. Gore & Associates, Inc.

  • 15.1.1 Company Overview

  • 15.1.2 Financial Performance

  • 15.1.3 Product Portfolio

  • 15.1.4 Strategic Initiatives

  • 15.1.5 SWOT Analysis

• 15.2 Medtronic plc

• 15.3 Terumo Corporation

• 15.4 Getinge AB

• 15.5 LeMaitre Vascular, Inc.

• 15.6 Abbott Laboratories

• 15.7 B. Braun Melsungen AG

• 15.8 BD (Becton, Dickinson and Company)

• 15.9 Cook Medical Technologies LLC

• 15.10 Artivion, Inc. (CryoLife)

• 15.11 MicroPort Scientific Corporation

• 15.12 Endologix, Inc.

• 15.13 Humacyte, Inc.

• 15.14 Maquet Holding B.V. & Co. KG (Getinge Group)

• 15.15 Vascular Graft Solutions Ltd.

16. Appendix

• 16.1 Abbreviations and Acronyms

• 16.2 List of Tables

• 16.3 List of Figures

• 16.4 About the Publisher

• 16.5 Research Process and Data Sources

17. Disclaimer